Objective To explore the clinical value of different dosage of valsartan in treatment of chronic heartfailure (CHF).
Methods 99 patient s with CHF were randomly divided into three groups: benazepril group (group A, 10 mg/d), conventional dose valsartan group (group B, 80 mg/d) and high dose valsartan group (groups C, 80 mg/d, 2 times per day). Levels of Angiotensin II (Ang II), aldosterone (ALD) and brain nat riuretic peptide (BNP) were detected, and the changes of left ventricular ejection fraction (LVEF) were measured before and 6 months after treatment.
Results BNP, ALD, Ang II were decreased significantly in 3 groups (p<0.05), while LVEF increased significantly (p<0.05) after the treatment. Compared with those of group A and B, BNP and ALD were significantly decreased while LVEF was significantly increased after treatment in group C (p<0.05). ALD in group B decreased significantly compared with that of group A (p<0.05), while the other indexes were not significantly changed.
Conclusions Valsartan, similar to benazepril, reverses ventricular remodelling and improves cardiac function, high dose valsartan reverses ventricular remodelling and improves cardiac function more effectively than benazepril and conventional dose valsartan.
- Chronic heart failure Benazepril Valsartan Left vent ricular ejection fraction